top of page

Skin cancers

BREAK-3 trial
2011
Melanoma - BRAF+
BRIM-3 trial
2011
Melanoma - BRAF+
coBRIM trial
2014
Melanoma - BRAF+
COMBI-v trial
2015
Melanoma - BRAF+
COMBI-d trial
2017
Melanoma - BRAF+
IMspire 150 trial
2020
Melanoma - BRAF+
HD-IL-2 meta-analysis
1999
Melanoma - metastatic
MDX-020-010 trial
2010
Melanoma - metastatic
SEER-metastasectomy analysis
2011
Melanoma - metastatic
CheckMate 069 trial, ipi/nivo vs ipi
2015
Melanoma - metastatic
CheckMate 037 trial
2015
Melanoma - metastatic
KEYNOTE-029 trial, pembro vs low ipi
2017
Melanoma - metastatic
KEYNOTE-006 trial
2017
Melanoma - metastatic
CheckMate 511 trial
2019
Melanoma - metastatic
CheckMate 067 trial
2019
Melanoma - metastatic
CheckMate 066 trial
2020
Melanoma - metastatic
IMMUNED trial
2020
Melanoma - metastatic
Tebentafusp in Metastatic Uveal Melanoma
2022
Melanoma - metastatic
E-1684 trial
1996
Melanoma - stage III
EORTC 18071 trial
2016
Melanoma - stage III
MSLT-II trial
2017
Melanoma - stage III
DeCOG-SLT trial
2019
Melanoma - stage III
KEYNOTE-054 Trial/EORTC-1325
2020
Melanoma - stage III
COMBI-AD trial
2020
Melanoma - stage III
CheckMate 238 trial
2020
Melanoma - stage III
E1609 trial
2020
Melanoma - stage III

BREAK-3 trial
Chapman PB et al, NEJM, 2011; PMID:21639808

Melanoma - BRAF+

Background: phase III RCT included 675 treatment naïve BRAF V600E+ patients with metastatic melanoma

Arm A: vemurafenib 960mg BID
Arm B: dacarbazine 1000mg/m2 IV q3wk

Primary end point: OS and PFS.

Interim analysis at 6mo demonstrated 74% reduction in progression and 63% relative reduction in death with vemurafenib (P=<.001) therefore crossover from dacarbazine to vemurafenib was recommended.

Conclusions: vemurafenib improved OS and PFS comparing to dacarbazine.

 

Summarized by Veli Bakalov, MD

 

Send a feedback

 

bottom of page